# Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

> **NCT00583128** · PHASE2 · COMPLETED · sponsor: **Ocera Therapeutics** · enrollment: 117 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** AST-120
- **DRUG:** Celphere® CP-305

## Key facts

- **NCT ID:** NCT00583128
- **Lead sponsor:** Ocera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2014-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00583128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00583128, "Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00583128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*